These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 26585243

  • 41. Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection.
    Qiu X, Kroeker A, He S, Kozak R, Audet J, Mbikay M, Chrétien M.
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5182-8. PubMed ID: 27297486
    [Abstract] [Full Text] [Related]

  • 42. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X, Yao C, Wei Y, Kou Z, Hu K.
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [Abstract] [Full Text] [Related]

  • 43. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.
    Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST.
    Virology; 2005 Feb 05; 332(1):20-7. PubMed ID: 15661137
    [Abstract] [Full Text] [Related]

  • 44. A cell-based high-throughput protocol to screen entry inhibitors of highly pathogenic viruses with Traditional Chinese Medicines.
    Yang Y, Cheng H, Yan H, Wang PZ, Rong R, Zhang YY, Zhang CB, Du RK, Rong LJ.
    J Med Virol; 2017 May 05; 89(5):908-916. PubMed ID: 27704591
    [Abstract] [Full Text] [Related]

  • 45. Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
    Capuzzi SJ, Sun W, Muratov EN, Martínez-Romero C, He S, Zhu W, Li H, Tawa G, Fisher EG, Xu M, Shinn P, Qiu X, García-Sastre A, Zheng W, Tropsha A.
    J Med Chem; 2018 Apr 26; 61(8):3582-3594. PubMed ID: 29624387
    [Abstract] [Full Text] [Related]

  • 46. [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].
    Wang LL, Chen Q, Zhou LN, Guo Y.
    Yao Xue Xue Bao; 2015 Dec 26; 50(12):1545-50. PubMed ID: 27169275
    [Abstract] [Full Text] [Related]

  • 47. Interferon-γ Inhibits Ebola Virus Infection.
    Rhein BA, Powers LS, Rogers K, Anantpadma M, Singh BK, Sakurai Y, Bair T, Miller-Hunt C, Sinn P, Davey RA, Monick MM, Maury W.
    PLoS Pathog; 2015 Dec 26; 11(11):e1005263. PubMed ID: 26562011
    [Abstract] [Full Text] [Related]

  • 48. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.
    Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger GG, White JM.
    PLoS Negl Trop Dis; 2017 Apr 26; 11(4):e0005540. PubMed ID: 28403145
    [Abstract] [Full Text] [Related]

  • 49. Identification of entry inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library.
    Beck S, Henß L, Weidner T, Herrmann J, Müller R, Chao YK, Grimm C, Weber C, Sliva K, Schnierle BS.
    Antiviral Res; 2016 Aug 26; 132():85-91. PubMed ID: 27241689
    [Abstract] [Full Text] [Related]

  • 50. [Establishment of a cell-based filovirus entry inhibitor evaluation system].
    Chen Q, Guo Y.
    Yao Xue Xue Bao; 2015 Dec 26; 50(12):1538-44. PubMed ID: 27169274
    [Abstract] [Full Text] [Related]

  • 51. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus.
    Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR.
    Antiviral Res; 2003 Mar 26; 58(1):47-56. PubMed ID: 12719006
    [Abstract] [Full Text] [Related]

  • 52. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
    Gaisina IN, Peet NP, Wong L, Schafer AM, Cheng H, Anantpadma M, Davey RA, Thatcher GRJ, Rong L.
    J Med Chem; 2020 Jul 09; 63(13):7211-7225. PubMed ID: 32490678
    [Abstract] [Full Text] [Related]

  • 53. A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals.
    Hoenen T, Groseth A, Callison J, Takada A, Feldmann H.
    Antiviral Res; 2013 Sep 09; 99(3):207-13. PubMed ID: 23751367
    [Abstract] [Full Text] [Related]

  • 54. High-Throughput Screening Assays for Dengue Antiviral Drug Development.
    Jabanathan SG, Xuan LZ, Ramanathan B.
    Methods Mol Biol; 2021 Sep 09; 2296():279-302. PubMed ID: 33977455
    [Abstract] [Full Text] [Related]

  • 55. Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease.
    Lane TR, Dyall J, Mercer L, Goodin C, Foil DH, Zhou H, Postnikova E, Liang JY, Holbrook MR, Madrid PB, Ekins S.
    Antiviral Res; 2020 Oct 09; 182():104908. PubMed ID: 32798602
    [Abstract] [Full Text] [Related]

  • 56. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.
    Haque A, Hober D, Blondiaux J.
    Antimicrob Agents Chemother; 2015 Oct 09; 59(10):5892-902. PubMed ID: 26248374
    [Abstract] [Full Text] [Related]

  • 57. An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.
    Nelson EV, Pacheco JR, Hume AJ, Cressey TN, Deflubé LR, Ruedas JB, Connor JH, Ebihara H, Mühlberger E.
    Antiviral Res; 2017 Oct 09; 146():21-27. PubMed ID: 28807685
    [Abstract] [Full Text] [Related]

  • 58. Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro.
    Kummer S, Lander A, Goretzko J, Kirchoff N, Rescher U, Schloer S.
    Emerg Microbes Infect; 2022 Dec 09; 11(1):195-207. PubMed ID: 34919035
    [Abstract] [Full Text] [Related]

  • 59. Inhibition of heat-shock protein 90 reduces Ebola virus replication.
    Smith DR, McCarthy S, Chrovian A, Olinger G, Stossel A, Geisbert TW, Hensley LE, Connor JH.
    Antiviral Res; 2010 Aug 09; 87(2):187-94. PubMed ID: 20452380
    [Abstract] [Full Text] [Related]

  • 60. Drug targets in infections with Ebola and Marburg viruses.
    Gene OG, Julia BE, Vanessa MR, Victoria WJ, Thomas GW, Lisa HE.
    Infect Disord Drug Targets; 2009 Apr 09; 9(2):191-200. PubMed ID: 19275706
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.